Hereditary and acquired thrombotic risk factors for chronic thromboembolic pulmonary hypertension
- PMID: 20182352
- DOI: 10.1097/MBC.0b013e328331e664
Hereditary and acquired thrombotic risk factors for chronic thromboembolic pulmonary hypertension
Abstract
The role of thrombosis and hereditary thrombotic risk factors in the pathogenesis of chronic thromboembolic pulmonary hypertension (CTEPH) and non-CTEPH is not clear. We retrospectively analyzed the frequency of hereditary and acquired thrombotic risk factors in 245 patients with pulmonary hypertension, of whom 45 had CTEPH and 200 had non-CTEPH. Nine of 31 (29%) white patients with CTEPH versus 10 of 129 (7.8%) patients with non-CTEPH were heterozygous for factor V Leiden (FVL; P = 0.001). Contrary to other studies, antiphospholipid antibodies (APA) were not increased. Elevated factor VIII (FVIII) and von Willebrand factor (VWF; >1.5 U/ml) were common in CTEPH and non-CTEPH, although significantly higher (P = 0.01 for FVIII and 0.009 for VWF) in CTEPH versus non-CTEPH. There was no correlation between FVIII-VWF and fibrinogen levels in the CTEPH group (P = 0.84 for FVIII and 0.49 for VWF) but a strong correlation between FVIII-VWF and fibrinogen in the non-CTEPH (P < 0.0001). There was no association between FVIII-VWF and WHO functional status in the CTEPH group although there was a strong correlation (P < 0.001) between the two parameters in the non-CTEPH group. For equivalent WHO functional class, FVIII levels were significantly higher (P = 0.007) in the CTEPH group. We have found no association between FVIII-VWF levels and oxygen saturation in both groups of patients. The results indicate different pathophysiologies for CTEPH and non-CTEPH. The elevation of FVIII and increased incidence of FVL gene polymorphisms in the CTEPH group support a primary role of thrombosis in aetiology.
Similar articles
-
Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation.Blood Coagul Fibrinolysis. 1999 Oct;10(7):409-16. Blood Coagul Fibrinolysis. 1999. PMID: 10695766
-
von Willebrand factor and factor VIII: C in acute cerebrovascular disease. Relationship to stroke subtype and mortality.Thromb Haemost. 1997 Jun;77(6):1104-8. Thromb Haemost. 1997. PMID: 9241740
-
High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension.Thromb Haemost. 2003 Sep;90(3):372-6. doi: 10.1160/TH03-02-0067. Thromb Haemost. 2003. PMID: 12958604
-
[Risk factors in chronic thromboembolic pulmonary hypertension].Arch Bronconeumol. 2009 Jun;45 Suppl 6:11-4. doi: 10.1016/S0300-2896(09)73497-0. Arch Bronconeumol. 2009. PMID: 20542195 Review. Spanish.
-
Risk factors for chronic thromboembolic pulmonary hypertension.Proc Am Thorac Soc. 2006 Sep;3(7):568-70. doi: 10.1513/pats.200605-108LR. Proc Am Thorac Soc. 2006. PMID: 16963535 Review.
Cited by
-
Prevalence of antiphospholipid (aPL) antibodies among patients with chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis.Intern Emerg Med. 2019 Jun;14(4):521-527. doi: 10.1007/s11739-018-02021-z. Epub 2019 Jan 2. Intern Emerg Med. 2019. PMID: 30603858
-
Diagnostic evaluation and management of chronic thromboembolic pulmonary hypertension: a clinical practice guideline.Can Respir J. 2010 Nov-Dec;17(6):301-34. doi: 10.1155/2010/704258. Can Respir J. 2010. PMID: 21165353 Free PMC article.
-
Epidemiology and Pathophysiology of Chronic Thromboembolic Pulmonary Hypertension: Risk Factors and Mechanisms.Methodist Debakey Cardiovasc J. 2016 Oct-Dec;12(4):195-198. doi: 10.14797/mdcj-12-4-195. Methodist Debakey Cardiovasc J. 2016. PMID: 28289493 Free PMC article. Review.
-
Incidence of chronic thromboembolic pulmonary hypertension in Thammasat University Hospital.Lung India. 2018 Sep-Oct;35(5):373-378. doi: 10.4103/lungindia.lungindia_158_18. Lung India. 2018. PMID: 30168454 Free PMC article.
-
Chronic thromboembolic pulmonary hypertension: detection, medical and surgical treatment approach, and current outcomes.Heart Fail Rev. 2016 May;21(3):309-22. doi: 10.1007/s10741-015-9518-3. Heart Fail Rev. 2016. PMID: 26739298 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous